Global In-vitro Colorectal Cancer Screening Tests Market to Reach US$ 1,590.8 Million by 2032, Catalyzed by Rising Incidences of Colorectal Cancer

June 08, 2022 | Healthcare

IMARC Group’s latest report, titled “In-vitro Colorectal Cancer Screening Tests Market Report by Product (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests), Imaging Type (Colonoscopy, Proctoscopy, CT Scan, Ultrasound, MRI, PET Scan), End User (Hospitals, Clinics, Diagnostic Laboratories, and Others), and Region 2024-2032,” finds that the global in-vitro colorectal cancer screening tests market size reached US$ 997.2 Million in 2023. In-vitro colorectal cancer screening tests refer to diagnostic procedures that aid in detecting adenomas, polyps, and symptoms of colorectal cancer (CRC), characterized by abnormal cell growth in the large intestine, colon, and rectum. Some of the most common CRC screening tests include fecal occult blood (FOB), lateral flow immuno, transferrin assays, panel DNA, methylated gene, biomarker, and guaiac FOB stool tests. They are performed using cameras to capture images of the digestive tract and transfer them to the recorder tied to the waist of the patient. In recent years, in-vitro CRC screening tests have gained immense traction across clinics, hospitals, and diagnostics laboratories as they are minimally invasive and enable timely cancer detection.

Global In-vitro Colorectal Cancer Screening Tests Market Trends:

The rising incidences of colorectal cancer (CRC) represent the primary factor driving the market growth. Besides this, the expanding geriatric population that is more prone to developing such chronic medical ailments is another major growth-inducing factor. Additionally, there has been a substantial shift toward minimally invasive (MI) diagnostic procedures among patients and healthcare professionals to minimize discomfort. In line with this, the growing awareness among the masses regarding the benefits of early detection and timely cancer treatment has augmented the demand for in-vitro CRC screening tests. For instance, the introduction of novel CRC screening tests that utilize genetic testing that assist in early detection, making treatment plans, preventing the spread of cancerous cells, and eliminating the risks of developing associated disorders has catalyzed the market growth. Apart from this, the implementation of favorable government initiatives mandating cancer screening tests is positively influencing the market growth. Other factors, including technological advancements in cancer screening, extensive investments in research and development (R&D) activities, and improving healthcare infrastructure, are also creating a favorable market outlook. Looking forward, IMARC Group expects the market value to reach US$ 1,590.8 Million by 2032, growing at a CAGR of 5.2% during the forecast period (2024-2032).

Market Summary:

  • Based on the product, the market has been divided into fecal occult blood tests (guaiac FOB stool test, immuno-FOB agglutination test, lateral flow immuno-FOB test, and immuno-FOB ELISA test), biomarker tests (tumor M2-PK stool test and transferrin assays), and CRC DNA screening tests (methylated gene testing and panel DNA tests). 
  • On the basis of the imaging type, the market has been classified into colonoscopy, proctoscopy, CT scan, ultrasound, MRI, and PET scan.
  • The market has been segregated based on the end user into hospitals, clinics, diagnostic laboratories, and others.
  • Region-wise, the market has been segmented into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa. 
  • The competitive landscape of the market has also been examined, with some of the key players being Beckman Coulter Inc. (Danaher Corporation), Eiken Chemical Co. Ltd., Epigenomics AG, Exact Sciences Corporation, Hemosure Inc., Immunostics Inc. (Boditech Med Inc.), Medline Industries LP, Merck KGaA, Qiagen N.V., Quest Diagnostics Incorporated, R-Biopharm AG, Siemens AG, and Sysmex Corporation.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Million
Segment Coverage Product, Imaging Type, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Beckman Coulter Inc. (Danaher Corporation), Eiken Chemical Co. Ltd., Epigenomics AG, Exact Sciences Corporation, Hemosure Inc., Immunostics Inc. (Boditech Med Inc.), Medline Industries LP, Merck KGaA, Qiagen N.V., Quest Diagnostics Incorporated, R-Biopharm AG, Siemens AG and Sysmex Corporation
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:


USA: +1-631-791-1145
Follow us on twitter : @imarcglobal

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global In-vitro Colorectal Cancer Screening Tests Market to Reach US$ 1,590.8 Million by 2032, Catalyzed by Rising Incidences of Colorectal Cancer
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-713-2163


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More